Assess R&D success and attrition rates across the entire pharma and biotech industry. Here are just some of the questions Pharmapredict can answer:

• How does your company’s R&D success rate compare to your competitor’s?
• How do the success rates of Phase I and Phase III drugs compare?
• Is there a significant difference between the success rates of cancer drugs versus antiviral drugs?

Pharmapredict contains data on all drugs developed since 1980. From this group of 35,000 drugs we have selected those that have either been successful ie launched, or unsuccessful – discontinued.  This equates to 29,000 drugs.

We have used these 29,000 drugs with a defined outcome to calculate the success, and inversely attrition, rates for every company, therapy group or specific therapy. You choose whether to analyse R&D success rates based on:

• The success rate of a company
• The success rate of drugs belonging to the same therapeutic group
  E.g. respiratory drugs
• The success rate of drugs belonging to the same specific therapy E.g. asthma drugs
• The success rate of all drugs – independent of company or therapy

Simply select one or many companies or therapies and you will immediately be presented with a tabular analysis of the probability of successful launch. A success rate is given for every phase of development. 
  
View results